0000000000140895

AUTHOR

Cristian Surcel

showing 3 related works from this author

Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update

2018

Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities. In addition, further survival prolongation by changing treatment paradigm in both metastasized hormone-sensitive and nonmetastatic castration-resistant disease …

MaleOncologymedicine.medical_specialtyCombination therapyCost effectivenessUrologyAntineoplastic AgentsDiseaselaw.invention03 medical and health sciencesProstate cancerchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineBone Density Conservation Agentsbusiness.industryAbiraterone acetateProstatic NeoplasmsBone metastasismedicine.diseaseZoledronic acidOncologychemistry030220 oncology & carcinogenesisDrug Therapy Combinationbusinessmedicine.drugUrologic Oncology: Seminars and Original Investigations
researchProduct

Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review

2021

Abstract Context The assessment of “soft” endpoints such as health-related quality of life (HRQOL) is increasingly relevant when evaluating the optimal treatment sequence of novel therapeutic options in patients with advanced prostate cancer (PCa). Objective To systematically review contemporary data regarding HRQOL outcomes in patients with advanced PCa. Evidence acquisition A systematic review of the literature published between January 2011 and March 2019 was performed using the PubMed/Medline Database. In total, 873 articles were screened, and 14 articles including 12 661 patients were selected for synthesis and included in the current analysis according to the Preferred Reporting Items…

MaleOncologymedicine.medical_specialtyUrologyHealth-related quality of lifeAbiraterone Acetate030232 urology & nephrologyContext (language use)Androgen deprivation therapy03 medical and health scienceschemistry.chemical_compoundMetastatic prostate cancer0302 clinical medicineQuality of lifeInternal medicineHumansMedicineEnzalutamideEuropean Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCastration-resistant prostate cancerbusiness.industryAdvanced prostate cancerApalutamideAbiraterone acetateFunctional Assessment of Cancer Therapy-ProstateAndrogen AntagonistsAdvanced prostate cancer; Castration-resistant prostate cancer; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; European Quality of Life 5-Dimensions; Functional Assessment of Cancer Therapy-Prostate; Health-related quality of life; Metastatic prostate cancerhumanitiesEuropean Quality of Life 5-DimensionsClinical trialProstatic Neoplasms Castration-ResistantSystematic reviewchemistry030220 oncology & carcinogenesisAndrogensQuality of LifebusinessOrchiectomy
researchProduct

Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?

2019

Recently, adoption of novel drugs for systemic treatment of metastatic prostate cancer has led to a striking improvement of response rate and survival in both hormone-sensitive and castration-resistant disease. In most cases, prostate cancer essentially depends on androgen receptor signaling axis, even in castration-resistant setting, and hence may be targeted by second generation hormonal therapy. However, a subset of patients bears androgen-independent cancer biology with a short-term response to hormonal treatment, early and extensive visceral metastases, low PSA levels and poor outcomes. Identification and specific management of these rapidly fatal malignancies is of an unmet medical ne…

Male0301 basic medicineOncologymedicine.medical_specialtyAntineoplastic Agents HormonalDiseaseNeuroendocrine differentiationSmall-cell carcinoma03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineBiomarkers TumormedicineHumansRadiology Nuclear Medicine and imagingResponse rate (survey)business.industryGeneral Medicinemedicine.diseaseAndrogen receptorProstatic Neoplasms Castration-Resistant030104 developmental biologyOncologyReceptors Androgen030220 oncology & carcinogenesisAndrogensAdenocarcinomaHormonal therapybusinessCancer Treatment Reviews
researchProduct